NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer Jun 21, 2022
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting May 10, 2022
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary May 9, 2022
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay Apr 25, 2022
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022 Apr 11, 2022
